← Back to Clinical Trials
Recruiting NCT06430346

NCT06430346 Exercise Prehabilitation for Locoregional Esophageal Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06430346
Status Recruiting
Phase
Sponsor H. Lee Moffitt Cancer Center and Research Institute
Condition Esophageal Cancer
Study Type INTERVENTIONAL
Enrollment 20 participants
Start Date 2024-05-21
Primary Completion 2027-05

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Exercise

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 20 participants in total. It began in 2024-05-21 with a primary completion date of 2027-05.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of the study is to examine the feasibility and acceptability of exercise "prehabilitation" for patients preparing for esophageal cancer resection (removal).

Eligibility Criteria

Inclusion Criteria: * Biopsy-proven locoregional esophageal cancer (LEC) * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Treatment plan including neoadjuvant chemoradiation therapy and surgical resection * Ability to read and speak English Exclusion Criteria: * Regular engagement in resistance training (2x/week targeting all major muscle groups) * Screen failure for exercise safety based on PAR-Q * Underlying unstable cardiac or pulmonary disease or symptomatic cardiac disease * Recent fracture or acute musculoskeletal injury that precludes ability to participate in resistance training safely * Numeric pain rating scale of 7 or more out of 10 * Myopathic or rheumatologic disease that impacts physical function

Contact & Investigator

Central Contact

Nathan Parker, PhD

✉ Nathan.Parker@moffitt.org

📞 813-745-6849

Principal Investigator

Nathan Parker, PhD

PRINCIPAL INVESTIGATOR

Moffitt Cancer Center

Frequently Asked Questions

Who can join the NCT06430346 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Esophageal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06430346 currently recruiting?

Yes, NCT06430346 is actively recruiting participants. Contact the research team at Nathan.Parker@moffitt.org for enrollment information.

Where is the NCT06430346 trial being conducted?

This trial is being conducted at Tampa, United States.

Who is sponsoring the NCT06430346 clinical trial?

NCT06430346 is sponsored by H. Lee Moffitt Cancer Center and Research Institute. The principal investigator is Nathan Parker, PhD at Moffitt Cancer Center. The trial plans to enroll 20 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology